• Johnson & Johnson has seen positive mid-June clinical and product updates, including strong TALVEY combination data in multiple myeloma and positive Phase 2/3 ENERGY results for IMAAVY in warm autoimmune hemolytic anemia.
  • Institutional investors like Warren Street Wealth Advisors and CPC Advisors have significantly increased their holdings in the company.
  • The company is also investing over $1 billion to expand its U.S. Vision manufacturing, contributing to a constructive market sentiment.